Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis
- 1 December 2001
- journal article
- Published by Elsevier BV in Urology
- Vol. 58 (6), 1008-1015
- https://doi.org/10.1016/s0090-4295(01)01405-4
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- CYTOKINE VARIATIONS IN PATIENTS WITH HORMONE TREATED PROSTATE CANCERJournal of Urology, 2000
- ELEVATED LEVELS OF CIRCULATING INTERLEUKIN-6 AND TRANSFORMING GROWTH FACTOR-beta 1 IN PATIENTS WITH METASTATIC PROSTATIC CARCINOMAJournal of Urology, 1999
- The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6.The Journal of Experimental Medicine, 1996
- Prediction of Progression Following Radical ProstatectomyThe American Journal of Surgical Pathology, 1996
- Soluble interleukin‐6 receptor as a prognostic factor in multiple myelomaBritish Journal of Haematology, 1996
- Soluble Interleukin 6 Receptor is Biologically Active In VivoCytokine, 1995
- Fresh tissue harvest for research from prostatectomy specimensThe Prostate, 1994
- Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volumeCancer, 1993
- Evidence for the involvement of interleukin 6 in experimental cancer cachexia.JCI Insight, 1992
- Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice.JCI Insight, 1991